Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Techulon Awarded $1.9M to Defeat “Superbugs”

By Pharmaceutical Processing | May 9, 2013

Techulon, Inc. has been selected by the Defense Advanced Research Projects Agency (DARPA) for a Phase II contract to advance its therapeutic program for multi-drug resistant bacteria, or ‘superbugs.’ This award drives Techulon’s development of a nanotherapeutic agent that will give the Department of Defense and hospitals the ability to rapidly respond and treat patients with life-threatening multi-drug resistant infections. Techulon successfully completed an early feasibility program of its technology platform in 2012 with DARPA leading up to the current award.

Drug-resistant bacteria are a pervasive and growing problem to both military and civilian healthcare facilities and create over $30B in cost and 100,000 deaths per year. Funding from DARPA will provide resources for Techulon to advance its technology through critical milestones toward human clinical trials.

“We are pleased to extend our work in Rapidly-Adaptable Therapeutics with DARPA. This program will lead to better therapies for wounded soldiers and civilians affected by multi-drug resistant hospital-acquired infections,” commented Dr. Joshua Bryson, CSO at Techulon.

Dr. Brett Malone, Techulon’s President commented, “Our partnership with DARPA helps us continue to build value in our clinical initiatives and ultimately have an impact on the healthcare industry with a new generation of therapeutics. Our approach is feasible in many disease areas, including drug-resistant infections, and we are excited to be working with the agency to solve such a devastating problem.”

 

Related Articles Read More >

GSK
GSK invests another $800M in Pennsylvania site expansions
This is a BD image of its major IV catheters manufacturing facility in Sandy, Utah, which the company said produces billions of molded components each year.
BD to invest billions in U.S. manufacturing
Diverse factory workers in yellow PPE suits checking production data with clipboard in modern industrial facility, Quality control inspector wearing masks and hairnets working in food or pharma plant
ISO 9001, 14001 and 45001 revisions: What changes and when to start
Artis BioSolutions announces new center of excellence in Spain
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE